Friday, January 29, 2016

Zika Virus: Fact Sheet

As Copied from the WHO Website;

Key facts

  • Zika virus disease is caused by a virus transmitted by Aedes mosquitoes.
  • People with Zika virus disease usually have a mild fever, skin rash (exanthema) and conjunctivitis. These symptoms normally last for 2-7 days.
  • There is no specific treatment or vaccine currently available.
  • The best form of prevention is protection against mosquito bites.
  • The virus is known to circulate in Africa, the Americas, Asia and the Pacific.

Introduction

Zika virus is an emerging mosquito-borne virus that was first identified in Uganda in 1947 in rhesus monkeys through a monitoring network of sylvatic yellow fever. It was subsequently identified in humans in 1952 in Uganda and the United Republic of Tanzania. Outbreaks of Zika virus disease have been recorded in Africa, the Americas, Asia and the Pacific.
  • Genre: Flavivirus
  • Vector: Aedes mosquitoes (which usually bite during the morning and late afternoon/evening hours)
  • Reservoir: Unknown

Signs and Symptoms

The incubation period (the time from exposure to symptoms) of Zika virus disease is not clear, but is likely to be a few days. The symptoms are similar to other arbovirus infections such as dengue, and include fever, skin rashes, conjunctivitis, muscle and joint pain, malaise, and headache. These symptoms are usually mild and last for 2-7 days.
During large outbreaks in French Polynesia and Brazil in 2013 and 2015 respectively, national health authorities reported potential neurological and auto-immune complications of Zika virus disease. Recently in Brazil, local health authorities have observed an increase in Zika virus infections in the general public as well as an increase in babies born with microcephaly in northeast Brazil. Agencies investigating the Zika outbreaks are finding an increasing body of evidence about the link between Zika virus and microcephaly. However, more investigation is needed before we understand the relationship between microcephaly in babies and the Zika virus. Other potential causes are also being investigated.

Transmission

Zika virus is transmitted to people through the bite of an infected mosquito from the Aedes genus, mainly Aedes aegypti in tropical regions. This is the same mosquito that transmits dengue, chikungunya and yellow fever.
Zika virus disease outbreaks were reported for the first time from the Pacific in 2007 and 2013 (Yap and French Polynesia, respectively), and in 2015 from the Americas (Brazil and Colombia) and Africa (Cape Verde). In addition, more than 13 countries in the Americas have reported sporadic Zika virus infections indicating rapid geographic expansion of Zika virus.

Diagnosis

Zika virus is diagnosed through PCR (polymerase chain reaction) and virus isolation from blood samples. Diagnosis by serology can be difficult as the virus can cross-react with other flaviviruses such as dengue, West Nile and yellow fever.

Prevention

Mosquitoes and their breeding sites pose a significant risk factor for Zika virus infection. Prevention and control relies on reducing mosquitoes through source reduction (removal and modification of breeding sites) and reducing contact between mosquitoes and people.
This can be done by using insect repellent; wearing clothes (preferably light-coloured) that cover as much of the body as possible; using physical barriers such as screens, closed doors and windows; and sleeping under mosquito nets. It is also important to empty, clean or cover containers that can hold water such as buckets, flower pots or tyres, so that places where mosquitoes can breed are removed.
Special attention and help should be given to those who may not be able to protect themselves adequately, such as young children, the sick or elderly.
During outbreaks, health authorities may advise that spraying of insecticides be carried out. Insecticides recommended by the WHO Pesticide Evaluation Scheme may also be used as larvicides to treat relatively large water containers.
Travellers should take the basic precautions described above to protect themselves from mosquito bites.

Treatment

Zika virus disease is usually relatively mild and requires no specific treatment. People sick with Zika virus should get plenty of rest, drink enough fluids, and treat pain and fever with common medicines. If symptoms worsen, they should seek medical care and advice. There is currently no vaccine available.

WHO Response

WHO is supporting countries to control Zika virus disease through:
  • strengthening surveillance;
  • building the capacity of laboratories to detect the virus;
  • working with countries to eliminate mosquito populations;
  • preparing recommendations for the clinical care and monitoring of persons with Zika virus infection; and
  • defining and supporting priority areas of research into Zika virus disease and possible complications.

Thursday, October 29, 2015

Global Tuberculosis Report 2015

 Cover image of the Global TB report 2015.









The World Health Organization has just published the Global Tuberculosis Report 2015. You can read the full report here

Thursday, October 1, 2015

Treat all people living with HIV, offer antiretrovirals as additional prevention choice for people at "substantial" risk

New policies could help avert more than 21 million deaths and 28 million new infections by 2030

News release
Anyone infected with HIV should begin antiretroviral treatment as soon after diagnosis as possible, WHO announced Wednesday. With its "treat-all" recommendation, WHO removes all limitations on eligibility for antiretroviral therapy (ART) among people living with HIV; all populations and age groups are now eligible for treatment.
The expanded use of antiretroviral treatment is supported by recent findings from clinical trials confirming that early use of ART keeps people living with HIV alive, healthier and reduces the risk of transmitting the virus to partners.
WHO/A. Fitrianto
WHO now also recommends that people at "substantial" risk of HIV should be offered preventive antiretroviral treatment. This new recommendation builds on 2014 WHO guidance to offer a combination of antiretroviral drugs to prevent HIV acquisition, pre-exposure prophylaxis (PrEP), for men who have sex with men. Following further evidence of the effectiveness and acceptability of PrEP, WHO has now broadened this recommendation to support the offer of PrEP to other population groups at significant HIV risk. PrEP should be seen as an additional prevention choice based on a comprehensive package of services, including HIV testing, counselling and support, and access to condoms and safe injection equipment.
New recommendations on early use of ART and expanded offer of PrEP are contained in WHO’s "Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV.” The new guideline stresses that, in order to effectively implement the recommendations, countries will need to ensure that testing and treatment for HIV infection are readily available and that those undergoing treatment are supported to adhere to recommended regimens and are retained in care.
The recommendations were developed as part of a comprehensive update of the "WHO consolidated guidelines on the use of antiretroviral drugs for preventing and treating HIV infection". This early release guideline is shared ahead of the full publication, slated for release later this year, because of their potential for public health impact.
Based on the new recommendations, the number of people eligible for antiretroviral treatment increases from 28 million to all 37 million people who currently live with HIV globally. Expanding access to treatment is at the heart of a new set of targets for 2020 with the aim to end the AIDS epidemic by 2030. These targets include 90% of people living with HIV being aware of their HIV infection, 90% of those receiving antiretroviral treatment, and 90% of people on ART having no detectable virus in their blood.
According to UNAIDS estimates, expanding ART to all people living with HIV and expanding prevention choices can help avert 21 million AIDS-related deaths and 28 million new infections by 2030. 

Source:WHO Website

Sunday, September 27, 2015

Sustainable Development Goals

On the 25 of September, 2015 The 193-Member United Nations General Assembly today formally adopted the 2030 Agenda for Sustainable Development, along with a set of bold new Global Goals, which Secretary-General Ban Ki-moon hailed as a universal, integrated and transformative vision for a better world. The Goals are displayed















For more information visit the UN website here

Thursday, September 24, 2015

Grant opportunities from the Bill & Melinda Gates Foundation


The Bill & Melinda Gates Foundation is inviting applications that address specific challenges defined in the grant programs below. For details and application instructions, please visit the new Grand Challenges website

Electrocardiography (ECG) Rhythm Interpretation

Dr. Tuzo Lyuu from Muhimbili National Hospital has been giving a series of lectures on ECG to PASADA Clinicians for the past three months. To get the notes for future reference please click here

Wednesday, September 23, 2015

Malaria death rates have plunged by 60% since 2000

The World Health Organization (WHO) this month, published a report which shows that since 2000 the Malaria Death Rates have plunged by 60%.

The report summarizes the remarkable progress seen, on a global and regional level, in reversing malaria mortality and incidence since 2000. It introduces malaria and the strategies used to fight the disease, outlines progress according to each of the MDG indicators, and highlights the main challenges that remain in controlling and eliminating this disease.

To learn more click here

Training in laboratory quality management and the WHO LQSI tool

Post-graduate training for medical laboratory professionals

This post-graduate training module was developed by KIT Biomedical Research for the World Health Organization especially for medical laboratory professionals (KIT Biomedical Research is designated as WHO Collaborating Centre for Laboratory Strengthening). During this course you’ll gain the theoretical background and the practical expertise required to efficiently implement a quality management system that complies with the requirements of the ISO 15189 international quality standard for medical/public health laboratories.For more information follow this link

Levels and Trends in Childhood Malnutrition

The World Health Organization has just published a Report on Levels and Trends of Childhood Malnutrition of the world. You can read it here

Sunday, March 22, 2015


Tanzania National Key Population Comprehensive Guidelines
The National AIDS Control Program has just released the Tanzania National Key Population Comprehensive Guidelines you can get the document by clicking here